LOGIN  |  REGISTER
Recursion

Bright Health to Host Third Quarter 2023 Earnings Conference Call on November 7, 2023

October 13, 2023 | Last Trade: US$7.29 2.98 69.14

MINNEAPOLIS / Oct 13, 2023 / Business Wire / Bright Health Group, Inc. ("Bright Health") (NYSE: BHG), the technology enabled, value-driven healthcare company, today announced it will report Third Quarter financial results before the financial markets open on Tuesday, November 7, 2023, followed by a conference call at 8:00 AM Eastern Time.

To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call.

A webcast of the earnings call may also be accessed via Bright Health’s Investor Relations page at investors.brighthealthgroup.com. The company suggests participants for the conference call dial in at least 15 minutes in advance of the call. A recording of the earnings call and presentation will be available on Bright Health’s Investor Relations page following the call.

About Bright Health Group

Bright Health Group is a technology enabled, value-driven healthcare company that organizes and operates networks of affiliate care providers to be successful at managing population risk. We focus on serving aging and underserved consumers that have unmet clinical needs through our Fully Aligned Care Model in Florida, Texas and California, some of the largest markets in healthcare where 26% of the U.S. aging population call home. We believe everyone should have access to personal, affordable, and high-quality healthcare. Our mission is to Make healthcare right. Together. For more information, visit www.brighthealthgroup.com.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB